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Human parvovirus 4 infections are primarily associated 
with parenteral exposure in western countries. By ELISA, 
we demonstrate frequent seropositivity for antibody to par-
vovirus 4 viral protein 2 among adult populations throughout 
sub-Saharan Africa (Burkina Faso, 37%; Cameroon, 25%; 
Democratic Republic of the Congo, 35%; South Africa, 
20%), which implies existence of alternative transmission 
routes.
H
uman parvovirus 4 (PARV4) was originally detected 
in plasma from a person at risk for infection with HIV 
through injection drug use (1). Genetic characterization of 
the complete genome sequence of the virus showed a dis-
tant relationship to existing genera within the family Par-
voviridae, although viruses showing 61%–63% sequence 
similarity to PARV4 have recently been described in pigs 
and cows (2), together likely meriting the designation of 
a new genus within the family. Although infections with 
PARV4 are not followed by long-term viremia, viral DNA 
sequences can likely be detected in tissues lifelong after ex-
posure (3–6), a form of latency or persistence shared with 
other human parvoviruses, e.g., human parvovirus B19, 
and adeno-associated viruses (6–8).
PARV4 differs strikingly from other parvoviruses 
in its epidemiologic associations and inferred routes of 
transmission. Initial studies of autopsy tissue demon-
strated high DNA detection frequencies among injection 
drug users co-infected with hepatitis C virus (HCV) in 
the United Kingdom, Italy, and Germany (3–5,9). Infec-
tion frequencies were higher in those who were HIV sero-
positive but almost absent in low-risk, HCV-negative and 
HIV-negative control populations. Despite these new in-
sights, studies based on autopsy or biopsy tissues are cum-
bersome and necessarily limited by sample availability 
and technical complexity.
The Study
To address gaps in knowledge about PARV4, we have 
recently developed an ELISA for antibodies to the viral 
protein 2 (VP2) of PARV4 genotype 1 to expand investiga-
tions of epidemiology and transmission of the virus (10). 
Larger scale screening conﬁ  rmed the previously noted as-
sociation between PARV4 infection and parenteral routes 
of exposure (injection drug use) in the United Kingdom and 
United States, much lower infection frequencies in HIV-in-
fected gay men, and zero seropositivity in low-risk controls. 
We additionally found serologic evidence for high rates of 
PARV4 exposure among persons with hemophilia exposed 
to nonvirally inactivated factor VIII/IX concentrates but a 
virtual absence of infection in sibling controls occupying 
the same households.
To investigate further the epidemiology of PARV4 
in sub-Saharan Africa, we assembled large sets of serum 
or plasma samples collected from a range of adult popula-
tions in several countries in Africa (Table). Samples were 
screened in duplicate by our previously described ELISA 
(10) by using protein puriﬁ  ed in parallel from empty bacu-
lovirus constructs as control antigen to minimize assay 
nonspeciﬁ   city. Low-risk orthopedic outpatient attendees 
(United Kingdom) and HIV-negative and HCV-negative 
nonremunerated blood donors (France) were used as nega-
tive control populations.
Serologic screening for PARV4 antibodies showed 
that the combined set of 360 blood donor and control sam-
ples from the United Kingdom and France were nonreac-
tive by ELISA (Table). In marked contrast, high rates of 
anti-PARV4 reactivity were detected in populations from 
sub-Saharan Africa. The highest rates were observed in 
Burkina Faso, where a frequency of 37% was recorded 
among a screened HIV-negative and HCV-negative blood 
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and 35% in Cameroon and Democratic Republic of the 
Congo, respectively, and lowest in South Africa (4% in 
HIV-negative persons). However, within the latter group, 
HIV-1–infected donors were signiﬁ  cantly more frequently 
seropositive for PARV4 than those who were not infected 
with HIV (36%; p<0.0001 by Fisher exact test). However, 
even with this risk factor, the overall prevalence was not 
as high as observed in the HIV-negative blood donors in 
Burkina Faso.
Conclusions
These ﬁ  ndings provide new and unexpected informa-
tion on the epidemiology and transmission of PARV4. 
First, although there is no evidence of PARV4 infection in 
nonpotentially exposed persons in Western countries (from 
the limited number currently surveyed), populations in sub-
Saharan Africa, particularly in Central Africa, show high 
rates of exposure that cannot plausibly be accounted for by 
parenteral exposure. For example, the highest rate of sero-
positivity was observed among blood donors in Burkina 
Faso and Democratic Republic of the Congo who were uni-
formly negative for HCV antibodies, as well as for HIV-1 
antibodies, by third-generation screening. In this setting, 
HCV infections are a frequent correlate of multiple blood 
transfusions and use of unsterilized needles in medical treat-
ment or vaccination, as well as injection drug use. The high 
rate of seropositivity among HCV screen-negative samples 
from all 4 countries in Africa provides strong evidence for 
an alternative route of PARV4 transmission that is largely 
or entirely absent in Western countries.
These ﬁ  ndings are consistent with PCR-based evidence 
for PARV4 viremia, presumably associated with acute in-
fection, among young children in rural Ghana (11), a coun-
try adjacent to Burkina Faso where similar conditions for 
virus transmission may exist. In this study group, parenteral 
exposure was not identiﬁ  ed, although infections were more 
frequent in families in low socioeconomic groups and those 
living near rivers and without a domestic water supply. In 
a separate study, autopsy samples from 2 HIV-infected Af-
rican men (from Nigeria and Democratic Republic of the 
Congo) were PARV4 positive, despite not being infected 
with HCV and without a history of parenteral exposure 
(12). Neither study identiﬁ  ed the speciﬁ  c risk factors and 
PARV4 infection sources.
It clearly is a challenge to conceive transmission routes 
for a virus that will not be directly transmitted among mem-
bers of the same household, as demonstrated by the hemo-
philiac sibling data for the United States (10). Hypotheses 
such as possible arthropod-borne or parasite-associated 
transmission require careful evaluation, bearing in mind 
that parvoviruses, in common with other DNA viruses, 
are highly host species speciﬁ  c, and no other instances of 
vector-borne transmission in this virus family have been 
recorded.
The second major observation was a substantial dif-
ference in the rate of PARV4 seropositivity between those 
who were HIV infected and those uninfected (in South 
Africa, 36% and 4%, respectively). This association with 
HIV appears initially consistent with higher frequencies of 
PARV4 seropositivity reported among HIV (and HCV) co-
infected injection drug users in Western countries. How-
ever, in the latter group, the association with HIV-1 was 
thought to reﬂ  ect a greater frequency of illicit injection 
with shared needles (4,9). Furthermore, low frequencies 
or absence of PARV4 infections were observed in HCV-
uninfected persons acquiring HIV-1 infection by sexual 
contact. How HIV-1 facilitates or becomes epidemiologi-
cally associated with PARV4 infection in HCV-negative 
South African blood donors thus remains unexplained in a 
population where HIV-1 infections are primarily acquired 
through sexual contact.
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Table. Seroprevalence of human parvovirus 4 antibodies in sub-Saharan African and control populations* 
Country Category  No.
Co-infection Mean year of birth 
(range) 
Collection
year
PARV4 positive, 
no. (%)  HIV† HCV‡ 
Burkina Faso  Blood donors  167 0 0 1982 (1951–1999)  2007  62 (37.1) 
Cameroon  General population  238 0 0 1968 (1962–1972)  2007  59 (24.8) 
Democratic Republic 
of the Congo 
Military population  221 2§ 0 1968 (1936–1986)  2007  78 (35.3) 
South Africa  Blood donors  
(HIV-positive) 
170 170 0 1976 (1945–1990)  2007  62 (36.4) 
South Africa  Blood donors  
(HIV-negative) 
180 0 0 NA 2009 8  (4.4) 
United Kingdom  General population  161 ND  ND  1950 (1937–1977)  2005  0
France  Blood donors  199 0 0 1965 (1943–1989)  2008  0
*HCV, hepatitis C virus; PARV4, human parvovirus 4; NA, not available; ND, screening not done.  
†HIV-1 screening methods: South Africa, France: fourth-generation ELISA. 
‡HCV screening methods: Burkina-Faso, South Africa, France: third-generation ELISA, recombinant immunoblot assay confirmation of positive results; 
Democratic Republic of the Congo: third-generation ELISA, exclusion of reactive samples; Cameroon: PCR-based screening, exclusion of PCR-positive 
samples. United Kingdom: not screened (ND), low risk background and absence of parenteral or HIV risk factors. 
§1 of 2 HIV-positive samples was seropositive for PARV4. PARV4 Infection in Sub-Saharan Africa
Although this study leaves many questions on the trans-
mission of PARV4 unanswered, the striking differences in 
seroprevalence and risk-group associations between sub-
Saharan Africa and Western countries provides the basis 
for future more detailed investigations of its transmission 
routes, epidemiology, and potential clinical outcomes of 
infections. The previously noted sequence homogeneity of 
PARV4 nucleotide sequences between variants detected in 
Western countries (4,13) is consistent with its recent global 
spread. A possible source in sub-Saharan Africa for PARV4 
would contain many potential parallels with the emergence 
and global spread of HIV-1 and HCV in the 20th century.
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